CN209662312U - A kind of external low-temperature anticoagulant system of CRRT - Google Patents
A kind of external low-temperature anticoagulant system of CRRT Download PDFInfo
- Publication number
- CN209662312U CN209662312U CN201920089718.0U CN201920089718U CN209662312U CN 209662312 U CN209662312 U CN 209662312U CN 201920089718 U CN201920089718 U CN 201920089718U CN 209662312 U CN209662312 U CN 209662312U
- Authority
- CN
- China
- Prior art keywords
- blood
- temperature
- control unit
- anticoagulant
- crrt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
Abstract
The utility model belongs to field of medical technology, more particularly to a kind of CRRT external low-temperature anticoagulant system and the method that is purified using the low-temperature anticoagulant system to blood, including CRRT blood purification instrument (1), controller (2), cooling control unit (3), heating control unit (4) and pipeline (10)；Cooling control unit (3) is first passed through before blood enters blood purification instrument (1) to cool down to blood, realizes low-temperature anticoagulant effect；Blood temperature is risen back body temperature temperature by heating control unit (4) before defeated the Huis' body again after blood purification instrument (1) purifies by blood.The advantages that the utility model realizes blood anticoagulant using physics mode, has Small side effects, easy to operate, and anticoagulant time is long.
Description
Technical field
The utility model belongs to field of medical technology more particularly to a kind of external low-temperature anticoagulant system of CRRT.
Background technique
In recent years, blood purification technology is clinically widely used in the rescue of all kinds of urgent patients, is important device
One of official's support means.Blood purification is the blood of patient to be led to external and pass through a kind of purification device, removes some of them
Morbid substance achievees the purpose that treat disease to purify blood.Continuity arteriovenous blood is proposed first from Kramer in 1977 etc.
Since liquid filters (CAVH) and is applied to clinic, with the continuous development of technology, by clinical practice in more than 20 years, people will
Continuous renal replacementtherapy (continuous renal is referred to as by a series of derivative treatment modes of CAVH
Replacement therapy, CRRT), CRRT means the various treatment sides that continuously can slowly remove water and solute at present
Method.The main target of CRRT (Continuous Renal Replacement Therapy, Sequential spot film) is clear
Except internal excess moisture, metabolic waste, poisonous substance, water and electrolyte disorder is corrected, it is ensured that nutritional support promotes graft function and clear
Except various cell factors, inflammatory mediator.The therapy is mainly used for that various cardiovascular functions are unstable, Metabolism or companion
The acute and chronic renal failure and Multiple Organ Dysfunction Syndrome of brain edema, acute respiratory distress syndrome, crush syndrome are anxious
The treatment of property necrotizing pancreatitis, chronic heart failure, hepatic encephalopathy, drug and toxic poisoning etc..Much due to its clinical application
Beyond traditional kidney trouble scope, advocate that answers is known as duration blood purification (continuous blood in recent years
Purification, CBP) it is more suitable.
In blood purification process, to guarantee going on smoothly for blood purification treatment, anticoagulant therapy is one of key factor.Mesh
Preceding common anticoagulant mode includes anticoagulant heparin method, the anticoagulant method of low molecular weight heparin, Anticoagulation without heparin, Regional Citrate Anticoagulation method；
In addition rare anticoagulant methods include that prostaglandin is anticoagulant, methylsulphur nanaimo division is anticoagulant, heparin sodium is anticoagulant and hirudin anticoagulant method.
It is ideal it is anticoagulant should be able to accomplish it is anticoagulant sufficiently, not influence or can improve the biocompatibility of filter film, action time short, anticoagulant
Effect is confined in filter, long-time service is without side-effects etc..Up to the present it there is no a kind of anti-coagulants that can fully meet above-mentioned
It is required that.For this purpose, we find new, effective anticoagulant mode.
Studies have shown that body center's temperature, which declines 2 DEG C, can obviously damage coagulation function, increase patient's hemorrhagic tendency.
We have found in the research of early period, by normal plasma standard, under condition of different temperatures detection (37 DEG C, 35 DEG C, 32 DEG C,
30 DEG C, 28 DEG C), average prothrombin time and part activation prothrombin time are extended as temperature reduces；It proves
Inhibiting coagulation factor level under normal circumstances, low temperature inhibits coagulation cascade to react, and leads to coagulation disorders.This is practical new
Type be exactly utilize low-temperature physics anticoagulant characteristic and design.
Utility model content
The utility model is achieved through the following technical solutions: blood is after femoral artery is drawn by pipeline by cooling control
Unit processed makes blood be rapidly decreased to the first temperature value, plays the role of low-temperature anticoagulant；Subsequent blood enters CRRT blood purification instrument, passes through
The purified blood of CRRT blood purification instrument is crossed by restoring coagulation function after heating control unit；Wherein, in the drop
First temperature sensor is set at the downstream line of warm control unit, is provided at the downstream line of the heating control unit
Second temperature sensor, first temperature sensor and the second temperature sensor are connect with controller respectively；The control
Device processed reads the blood temperature data of first temperature sensor and second temperature sensor acquisition and controls the drop
The operating of warm control unit and heating control unit, so that blood reaches the first temperature after flowing through the cooling control unit
Be worth, flow through heating control unit after reach second temperature value；Wherein, the cooling control unit include compressor, it is evaporator, swollen
Swollen valve, condenser and pipeline；The compressor, evaporator, expansion valve, condenser are sequentially connected by pipeline；The heating control
Unit heats blood using electric heating wire.
Further, first temperature value is 28-35 degree, and the second temperature value is 36-37 degree；
Further, first temperature value is 32 degree.
Preferably, the CRRT blood purification instrument uses the blood cleaning equipment of this field routine, such as Sweden's treasure
CRRT blood purification instrument, German Fresenius CRRT blood purification instrument, Beijing mighty force CRRT blood purification instrument；
The beneficial effects of the utility model are:
1. Physical temperature-lowering, temperature fall time are shorter.The external low-temperature anticoagulant system of CRRT provided by the utility model, by using
The additional temperature-controlling system that air cools and heats, using the method for pure Physical temperature-lowering, temperature that is simple, quickly adjusting patient blood
Degree completes blood purification.The time of this cooling means cooling is very short, it is desirable that when from blood end is drawn by blood extraction arrival filter
Reach target temperature, leaves and be restored to normal body temperature before filter returns in vivo, cooling, rewarming time are within 1min.Using
Pure physics temperature control mode, good cooling effect are not easy to cause the accident.
2. of simple structure and low cost.It will be apparent that system structure provided by the utility model is simple, it is easy to operate, at
This is cheap, can be promoted on a large scale.
Detailed description of the invention
Fig. 1 is the structural schematic diagram of the utility model CRRT condenser system
Fig. 2 is the structural schematic diagram for constituting temperature control unit 5
Specific embodiment
The utility model is further illustrated with embodiment below, but the utility model is not intended to be limited thereto.Following implementation
Test method without specific conditions in example, usually according to normal condition, or according to the normal condition proposed by manufacturer.
The composition of 1.CRRT low temperature blood purification system
Referring to attached drawing 1-2, the utility model provides a kind of external low-temperature anticoagulant system of CRRT, and blood is drawn by femoral artery
So that blood is rapidly decreased to the first temperature value by cooling control unit 3 by pipeline 10 afterwards, plays the role of low-temperature anticoagulant；Subsequent blood
Liquid enters CRRT blood purification instrument 1, after the purified blood of the CRRT blood purification instrument 1 is by heating control unit 4
Restore coagulation function；Wherein, first temperature sensor 12 is set at the downstream line of the cooling control unit 3, described
Second temperature sensor 13 is provided at the downstream line for the control unit 4 that heats up, first temperature sensor 12 and described the
Two temperature sensors 13 are connect with controller 2 respectively；The controller 2 reads first temperature sensor 12 and described second
The blood temperature data of the acquisition of temperature sensor 13 and the operating for controlling the cooling control unit 3 and the control unit 4 that heats up, from
And reach the second temperature after enabling blood flow through and reach the first temperature value after the cooling control unit 3, flowing through heating control unit 4
Angle value；Wherein, the cooling control unit includes compressor 6, evaporator 7, expansion valve 8, condenser 9 and pipeline 11；The pressure
Contracting machine 6, evaporator 7, expansion valve 8, condenser 9 are sequentially connected by pipeline 11；The heating control unit 4 uses electric heating wire pair
Blood is heated.Wherein, first temperature value is 28-35 degree, and preferably 32 all, and the second temperature value is 36-37 degree.
It, can be using following step when needing the external low-temperature anticoagulant system using the utility model to purify blood
It is rapid:
(1) CRRT blood evolution instrument 1 is opened, blood is entered into CRRT blood evolution instrument after femoral artery extraction；
(2) start controller 2, and set the first temperature value and second temperature value；
(3) cooling control unit 3 and heating control unit 4 start that blood temperature is adjusted, and blood is flowed along pipeline 10
Through the control unit 3 that cools down, blood temperature is reduced rapidly, low temperature blood is obtained, passes through CRRT blood purification instrument 1 and purified,
Heating control unit 4 is passed through later, blood is brought rapidly up and is restored to body temperature blood, restores coagulation function.
Working principle and process
A method of purification blood when operation, starts controller 2, so that CRRT blood purification instrument 1 is started to work, temperature
Degree control unit 5 starts to adjust temperature, and the blood of femoral artery outflow flows through cooling control unit 3 along pipeline 10, reduces rapidly blood
Liquid temperature obtains 32 DEG C of low temperature blood, passes through CRRT blood purification instrument 1 and purified, and it is single to pass through heating control later
Member 4 is brought rapidly up blood and is restored to 36.4 DEG C of body temperature blood, restores coagulation function.
Different from the prior art, the past research method is mainly using chemical blood anticoagulant method.Chemical blood
Anticoagulant methods detection method and monitoring index are had nothing in common with each other, main to monitor in coagulation function such as whole body anticoagulant heparin method
Activated partial thromboplastin time (is abbreviated as APTT), and every 4-6 hours monitoring is primary, and maintenance target APTT is 60-80s.And office
By reaching anticoagulant effect by chelating calcium ion in local citric acid in vitro circuit, then portion's citrate anticoagulation scheme is then
By being transfused calcium ion to body to offset the anticoagulation of citric acid, monitoring index be by filter after, pipeline free calcium
And the concentration of internal free calcium, it is respectively maintained at 0.3-0.4mmol/L and 1.0-1.2mmol/L.
Different from above two chemical anticoagulant methods, the utility model is using low-temperature anticoagulant method, for blood coagulation function
Energy, platelet function, coagulation factor activity etc. have different degrees of influence.The monitoring index that we choose is that monitoring influences to coagulate
APTT in blood function, the APTT of monitoring in every 6 hours, makes the APTT of target blood maintain 45-65s, to reach anticoagulant mark
It is quasi-.
Experimental result
The blood APTT that pipeline flows through after measurement cooling control unit 3, heating control unit 4 respectively, adjusts temperature control device,
The APTT of monitoring in every 6 hours makes the APTT of target blood maintain 45-65s, and the visible blood fluidity of naked eyes is good, reaches low
The anticoagulant requirement of temperature.
Claims (3)
1. a kind of external low-temperature anticoagulant system of CRRT, which is characterized in that blood is passed through after femoral artery is drawn by pipeline (10)
Crossing cooling control unit (3) makes blood be rapidly decreased to the first temperature value, plays the role of low-temperature anticoagulant；Subsequent blood enters CRRT blood
Liquid purification instrument (1) restores solidifying after the purified blood of the CRRT blood purification instrument (1) is by heating control unit (4)
Blood function；Wherein, the first temperature sensor (12) are set at the downstream line of cooling control unit (3), in the liter
It is provided with second temperature sensor (13) at the downstream line of warm control unit (4), first temperature sensor (12) and institute
Second temperature sensor (13) is stated to connect with controller (2) respectively；The controller (2) reads first temperature sensor
(12) and the second temperature sensor (13) acquisition blood temperature data and control the cooling control unit (3) and heat up
The operating of control unit (4), so that blood reaches the first temperature value after flowing through the cooling control unit (3), flows through liter
Reach second temperature value after warm control unit (4)；Wherein, the cooling control unit include compressor (6), it is evaporator (7), swollen
Swollen valve (8), condenser (9) and pipeline (11)；The compressor (6), evaporator (7), expansion valve (8), condenser (9) are by pipeline
(11) it is sequentially connected；The heating control unit (4) heats blood using electric heating wire.
2. external low-temperature anticoagulant system according to claim 1, which is characterized in that first temperature value is 28-35 degree,
The second temperature value is 36-37 degree.
3. external low-temperature anticoagulant system according to claim 2, which is characterized in that first temperature value is 32 degree.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811260759 | 2018-10-26 | ||
| CN2018112607598 | 2018-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN209662312U true CN209662312U (en) | 2019-11-22 |
Family
ID=65873242
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910046687.5A Pending CN109550096A (en) | 2018-10-26 | 2019-01-18 | A kind of external low-temperature anticoagulant system of CRRT and blood purification method |
| CN201920089718.0U Expired - Fee Related CN209662312U (en) | 2018-10-26 | 2019-01-18 | A kind of external low-temperature anticoagulant system of CRRT |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910046687.5A Pending CN109550096A (en) | 2018-10-26 | 2019-01-18 | A kind of external low-temperature anticoagulant system of CRRT and blood purification method |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN109550096A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109550096A (en) * | 2018-10-26 | 2019-04-02 | 南京鼓楼医院 | A kind of external low-temperature anticoagulant system of CRRT and blood purification method |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6775996B2 (en) * | 2002-02-22 | 2004-08-17 | Advanced Thermal Sciences Corp. | Systems and methods for temperature control |
| CZ300266B6 (en) * | 2008-01-22 | 2009-04-01 | Univerzita Karlova v Praze, Lékarská fakulta v Plzni | Method of reducing blood-clotting time in the circuit of kidney function substitution apparatus and device for making the same |
| CN104083810A (en) * | 2014-07-16 | 2014-10-08 | 周飞虎 | Double-layer tube circulating cooling system for CRRT |
| ES2858518T3 (en) * | 2014-08-14 | 2021-09-30 | Medivance Inc | System and method for extracorporeal temperature control |
| PL2995329T3 (en) * | 2014-09-15 | 2017-07-31 | Gambro Lundia Ab | Apparatus for extracorporeal treatment of blood and method of control of a blood-warming device in an extracorporeal blood treatment apparatus |
| CN105363079A (en) * | 2015-11-11 | 2016-03-02 | 吉林大学 | Blood-recovering blood transfusion apparatus |
| CN205494503U (en) * | 2016-01-25 | 2016-08-24 | 孔丽丽 | Two -way temperature sensing heating system of CRRT |
| JP6794713B2 (en) * | 2016-08-18 | 2020-12-02 | ニプロ株式会社 | Blood purification device |
| CN109550096A (en) * | 2018-10-26 | 2019-04-02 | 南京鼓楼医院 | A kind of external low-temperature anticoagulant system of CRRT and blood purification method |
-
2019
- 2019-01-18 CN CN201910046687.5A patent/CN109550096A/en active Pending
- 2019-01-18 CN CN201920089718.0U patent/CN209662312U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109550096A (en) * | 2018-10-26 | 2019-04-02 | 南京鼓楼医院 | A kind of external low-temperature anticoagulant system of CRRT and blood purification method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109550096A (en) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hetzel et al. | Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration | |
| US8158157B2 (en) | Multi-part substitution infusion fluids and matching anticoagulants | |
| EP1176969B1 (en) | Substitution infusion fluid and citrate anticoagulation | |
| Apsner et al. | Simplified citrate anticoagulation for high-flux hemodialysis | |
| CN209662312U (en) | A kind of external low-temperature anticoagulant system of CRRT | |
| Pezzi et al. | The use of coupled plasma filtration adsorption in traumatic rhabdomyolysis | |
| Wang et al. | Application of simplified regional citrate anticoagulation in hemodialysis patients with high risk of bleeding | |
| US20180050148A1 (en) | Methods for delivering regional citrate anticoagulation (rca) during extracorporeal blood treatments | |
| CN106964009B (en) | Preparation and adjustment method of CRRT (continuous reverse transcription) local citric acid anticoagulation displacement solution | |
| Artunc et al. | Removal of dabigatran is superior by sustained low efficient dialysis (SLED) compared to intermittent hemodialysis | |
| de Groot et al. | Large-pore hemodialytic procedures in pigs with ischemic hepatic necrosis; a randomized study. | |
| Hartmann et al. | Citrate anticoagulation and activation of the complement system | |
| Wang | Blood Purification in the Management of Cardiorenal Organ Failure in Critical Patients with COVID-19 in ICU: A Review | |
| Onichimowski et al. | Practical issues of regional anticoagulation during continuous renal replacement therapy. | |
| Schure | Cardiopulmonary bypass in infants and children: what's new? | |
| Xiao-hong et al. | Effect of sodium citrate anticoagulation in Hemodiafiltration | |
| Viggiano et al. | Plasma Calcium Concentration Modifies the Blood Sodium During Hemodialysis: Lessons from Hard Water Syndrome | |
| Weber et al. | A novel detoxification device for the treatment of hepatic failure (HF) | |
| Conrad et al. | Multiphysics finite element model of small solute transport in hollow fiber hemofilter membranes | |
| Botto et al. | BIOCOMPATIBILITY ASPECTS OF THE GRADIFLOW™ IN RENAL DIALYSIS | |
| Wuepper et al. | The use of electrolytic clearance to determine urea distribution volume | |
| Rudich et al. | EXTRACORPOREAL SUPPORT FOR NON-HEART-BEATING ORGAN DONORS: LOGISTICS AND TECHNIQUES | |
| Balogun et al. | FRACTIONAL EXCRETION OF UREA (FEur), NKF-DOQI GUIDELINES FOR INITIATION OF DIALYSIS & EFFECT ON US ESRD POPULATION | |
| Lindsay et al. | BODY WATER COMPARTMENT AND BLOOD VOLUME CHANGES DURING HD ULTRAFILTRATION | |
| Crabtree | CLINICAL BIODURABILITY OF ALIPHATIC POLYETHER-BASED POLYURETHANES AS PERITONEAL DIALYSIS CATHETERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191122 Termination date: 20210118 |